Elective administration of low dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypasssurgery for congenital heart disease does not shorten time to chest closure or reduce blood loss or need for transfusions:a randomized, double-blind, parallel group, plcebo controlled studyof rFVIIa and standardhaemostatic replacement therapy versus standard haemostatic therapy - Ekert, H; Brizard, C; Eyers, R; Cochrane, A (Blood Coagul Fibrinol, 2006)